EQS-Adhoc: Merck KGaA: Merck KGaA bestätigt Gespräche mit Springworks Therapeutics, Inc. zu möglicher Übernahme
|
EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme Darmstadt, 10. Februar 2025 - Merck KGaA („Merck“) reagiert auf Presseberichte und bestätigt fortgeschrittene Gespräche mit Springworks Therapeutics, Inc. Merck bestätigt auch, dass keine rechtlich bindende Vereinbarung getroffen wurde. Es gibt keine Gewissheit, dass eine Transaktion zustande kommen wird. Außerdem müssen noch kritische Bedingungen erfüllt werden.
Ende der Insiderinformation Kontakt Merck KGaA Dr. Gangolf Schrimpf Merck KGaA Frankfurter Straße 250 64293 Darmstadt Deutschland Telefon: +49 6151 729591 E-Mail: gangolf.schrimpf@merckgroup.com Internet: https://www.merckgroup.com/ ISIN: DE0006599905 WKN: 659990 Indizes: DAX Börsen: Regulierter Markt in Frankfurt am Main (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; Terminbörse EUREX; London, SIX Ende der Insiderinformation
10.02.2025 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. |
| Sprache: | Deutsch |
| Unternehmen: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Deutschland | |
| Telefon: | +49 (0)6151 72 - 2702 |
| E-Mail: | insiderregister@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indizes: | DAX |
| Börsen: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 2084015 |
| Ende der Mitteilung | EQS News-Service |
|
|
2084015 10.02.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 16.152,00 | 17.534,00 | 19.687,00 | 22.232,00 | 20.993,00 | 21.156,00 | 22.400,00 | |
| EBITDA1,2 | 4.066,00 | 4.923,00 | 5.946,00 | 6.504,00 | 5.489,00 | 5.779,00 | 6.200,00 | |
| EBITDA-Margin3 | 25,17 | 28,08 | 30,20 | 29,26 | 26,15 | 27,32 | 27,68 | |
| EBIT1,4 | 2.120,00 | 2.985,00 | 4.179,00 | 4.474,00 | 3.609,00 | 3.645,00 | 4.000,00 | |
| EBIT-Margin5 | 13,13 | 17,02 | 21,23 | 20,12 | 17,19 | 17,23 | 17,86 | |
| Net Profit (Loss)1 | 1.324,00 | 1.994,00 | 3.065,00 | 3.339,00 | 2.834,00 | 2.786,00 | 3.075,00 | |
| Net-Margin6 | 8,20 | 11,37 | 15,57 | 15,02 | 13,50 | 13,17 | 13,73 | |
| Cashflow1,7 | 2.856,00 | 3.477,00 | 4.616,00 | 4.259,00 | 3.784,00 | 4.586,00 | 4.730,00 | |
| Earnings per share8 | 3,04 | 4,57 | 7,03 | 7,65 | 6,49 | 6,39 | 7,05 | |
| Dividend per share8 | 1,30 | 1,40 | 1,85 | 2,20 | 2,20 | 2,20 | 2,40 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Merck | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 659990 | DE0006599905 | KGaA | 52.673,34 Mio € | 20.10.1995 | Halten | 8FXCVMW3+5C |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 14,87 | 23,56 | 0,63 | 20,29 | 1,78 | 11,49 | 2,49 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 2,20 | 2,20 | 2,20 | 1,79% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 25.04.2025 | 15.05.2025 | 07.08.2025 | 13.11.2025 | 06.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,50% | -17,75% | -12,29% | -19,14% | +789,13% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
